Recent research in public health projects that at least half of the US adult population will be obese by 2030, with at least a quarter projected to be severely obese by that time. The obesity epidemic along with uncontrolled diabetes dramatically worsen health outcomes and health spending in the US and clearly health providers have a call to action to stem the tide. We will be joined by Dr. Amy Meister, Chief Medical Health and Wellness Officer at the UPMC Health Plan, and by Dr. Amy Donihi, Professor of Pharmacy and Therapeutics at the University of Pittsburgh SOM to discuss novel strategies to target these two all-too-common conditions. We will be provided with a review of SGLT-2 inhibitors and GLP-1 agonists and clinical data outcomes on these comorbidities, as well as strategies to prevent diabetes and obesity using large health insurance networks.

Department of Medicine Grand Rounds
October 5, 2021

Changing the Curve of Patient Outcome in Diabetes and Obesity Management: GLP-1 receptor agonists & SGLT2 inhibitors

6:56  Amy Donihi, PharmD
Professor, Pharmacy and Therapeutics
University of Pittsburgh School of Pharmacy

30:15  Amy Meister, DO, MRO
Chief Medical Health and Wellness Officer
Workpartners and Commercial Products
UPMC Health Plan


View Presentation